Literature DB >> 30641522

Asymptomatic Primary Hyperparathyroidism.

Bart L Clarke.   

Abstract

Asymptomatic primary hyperparathyroidism has become the most common presentation of primary hyperparathyroidism in Europe and North America, and an increasingly common presentation in other parts of the world. As many as 25% of asymptomatic patients may develop indications for parathyroidectomy when followed long-term for up to 15 years. Patients who remain asymptomatic should be monitored for the development of complications that justify surgery. Patients who become symptomatic should be referred for surgery. Surgery may improve quality of life even in patients who remain asymptomatic.
© 2019 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2018        PMID: 30641522     DOI: 10.1159/000491035

Source DB:  PubMed          Journal:  Front Horm Res        ISSN: 0301-3073            Impact factor:   2.606


  4 in total

Review 1.  [Asymptomatic primary hyperparathyroidism : Operation or observation?]

Authors:  Katja Gollisch; Heide Siggelkow
Journal:  Internist (Berl)       Date:  2021-03-12       Impact factor: 0.743

2.  DXA-Based Bone Strain Index: A New Tool to Evaluate Bone Quality in Primary Hyperparathyroidism.

Authors:  Gaia Tabacco; Anda M Naciu; Carmelo Messina; Gianfranco Sanson; Luca Rinaudo; Roberto Cesareo; Stefania Falcone; Silvia Manfrini; Nicola Napoli; John P Bilezikian; Fabio M Ulivieri; Andrea Palermo
Journal:  J Clin Endocrinol Metab       Date:  2021-07-13       Impact factor: 5.958

3.  Diagnostic performance of the calcium/phosphate ratio for primary hyperparathyroidism in southwest China.

Authors:  Mengting Yin; Qianhui Liu; Qingzhong Wang; Yong He; Haolan Song; Xin Nie; Guixing Li
Journal:  Endocr Connect       Date:  2021-10-25       Impact factor: 3.335

4.  Differences in Clinicopathological Characteristics of Papillary Thyroid Carcinoma between Symptomatic and Asymptomatic Patients with Primary Hyperparathyroidism.

Authors:  Yuan Liu; Siyi Guo; Shaowei Sang; Jinbo Liu; Lin Qi; Bin Lv; Xiaoli Zhang
Journal:  Int J Endocrinol       Date:  2021-05-31       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.